價(jià)格 | 詢價(jià) |
包裝 | 1盒 |
最小起訂量 | 1盒 |
發(fā)貨地 | 上海 |
更新日期 | 2025-01-13 |
中文名稱:Amiloride HCl dihydrate | 英文名稱:Amiloride HCl dihydrate |
CAS:17440-83-4 | 品牌: 一研 |
保存條件: Store at -20°C | 產(chǎn)品類別: 抑制劑 |
Cas : 17440-83-4 |
產(chǎn)品屬性:
產(chǎn)品名稱 | 規(guī)格 | CAS號 | 型號 |
Amiloride HCl dihydrate | 10mM (in 1mL DMSO) 50mg | 17440-83-4 | EY-Y0165037 |
Cas No.17440-83-4
別名
化學(xué)名 3,5-diamino-6-chloro-N-(diaminomethylidene)pyrazine-2-carboxamide;dihydrate;hydrochloride
分子式 C6H8ClN7O.HCl.2H2O
分子量 302.12
溶解度 ≥ 14.05mg/mL in DMSO
儲存條件 Store at -20°C
General tips For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.
Shipping Condition Evaluation sample solution : ship with blue ice
All other available size: ship with RT , or blue ice upon request
產(chǎn)品描述:
Amiloride hydrochloride dihydrate is an inhibitor of both Epithelial sodium channel (ENaC) and urokinase-type plasminogen activator receptor (uTPA).
Amiloride hydrochloride dihydrate is a potent epithelial sodium channels (ENaCs) blocker. Amiloride is highly concentrated in the plasma 15 to 30 minutes following the injections. 2 mg/kg dose of Amiloride hydrochloride dihydrate has no effect on blood pressure, heart rate, mesenteric vascular resistance, or hindquarters vascular resistance as compare to the baseline measurements (n=7). Over a 2 hour period, Amiloride hydrochloride dihydrate elicits negligible responses in arterial pressure (-1±1 mmHg) and heart rate (-10±6 bpm/min) as compare to baseline levels. Results show an Amiloride hydrochloride dihydrate dose-related response pattern for the c-Fos activation in the area postrema (AP). Even at the lowest dose of Amiloride hydrochloride dihydrate (0.1 mg/kg), the number of c-Fos labeled neurons in the AP is statistically different from the control rats at a p<0.01 level[1].
References:
[1]. Miller RL, et al. Blockade of ENaCs by amiloride induces c-Fos activation of the area postrema. Brain Res. 2015 Mar 19;1601:40-51.
[2]. Xu LB, et al. Amiloride, a urokinase-type plasminogen activator receptor (uTPA) inhibitor, reduces proteinurea in podocytes. Genet Mol Res. 2015 Aug 14;14(3):9518-29.
成立日期 | 2014-06-05 (11年) | 注冊資本 | 100 |
員工人數(shù) | 50-100人 | 年?duì)I業(yè)額 | ¥ 100萬以內(nèi) |
主營行業(yè) | 生化試劑,抗體,細(xì)胞培養(yǎng),分子生物學(xué),免疫安全 | 經(jīng)營模式 | 工廠,試劑 |
產(chǎn)品名稱 | 價(jià)格 | 公司名稱 | 報(bào)價(jià)日期 | |
---|---|---|---|---|
¥660.00 |
VIP9年
|
北京索萊寶科技有限公司
|
2025-01-13 | |
詢價(jià) |
VIP6年
|
成都彼樣生物科技有限公司
|
2025-01-10 | |
詢價(jià) |
VIP5年
|
陜西締都醫(yī)藥化工有限公司
|
2024-12-18 | |
¥474.90 |
VIP1年
|
上海阿拉丁生化科技股份有限公司
|
2024-11-29 | |
¥6208.90 |
VIP13年
|
上海阿拉丁生化科技股份有限公司
|
2024-10-31 | |
詢價(jià) |
南京百鑫德諾生物科技有限公司
|
2024-09-26 | ||
詢價(jià) |
湖北隆信化工實(shí)業(yè)有限公司
|
2023-02-20 | ||
¥4800.00 |
武漢大華偉業(yè)醫(yī)藥化工有限公司
|
2019-11-26 | ||
¥4300 |
深圳市思美泉生物科技有限公司(武漢分部)
|
2019-11-26 | ||
¥4300 |
廣州市虎傲化工有限公司
|
2019-11-26 |